Purpose of this Study
We are doing this study to find out if an investigational drug called tocilizumab (the study drug) will lead to better outcomes after lung transplantation when it is combined with standard anti-rejection medicines.
Who Can Participate?
Eligibility
Adults ages 18+ who are on the list to receive a lung transplant.
For more information about who can join this study, please contact the study team at <a href= "mailto: kathleen.lane@duke.edu">mailto: kathleen.lane@duke.edu.</a>
For more information about who can join this study, please contact the study team at <a href= "mailto: kathleen.lane@duke.edu">mailto: kathleen.lane@duke.edu.</a>
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
If choose to join this study, you will:<ul>
<li>Get a random assignment (like a coin flip) to take the study drug or placebo (an inactive substance)</li>
<li>Take the study drug or placebo once a month for five months after your lung transplant</li>
<li>Have blood draws</li>
<li>Have lung biopsy samples collected</li>
<li>Have information collected from your medical record</li>
<li>Have study visits for up to 3 years after your lung transplant</li></ul>
<li>Get a random assignment (like a coin flip) to take the study drug or placebo (an inactive substance)</li>
<li>Take the study drug or placebo once a month for five months after your lung transplant</li>
<li>Have blood draws</li>
<li>Have lung biopsy samples collected</li>
<li>Have information collected from your medical record</li>
<li>Have study visits for up to 3 years after your lung transplant</li></ul>
Locations
Duke University Hospital
Visit Timing
Weekdays
Weekends
Evenings
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
TARGETING INFLAMMATION AND ALLOIMMUNITY IN LUNG TRANSPLANT RECIPIENTS
WITH TOCILIZUMAB (ALL IN LUNG)
WITH TOCILIZUMAB (ALL IN LUNG)
Principal Investigator
Matthew
Hartwig
Protocol Number
PRO00113759
NCT ID
NCT06033196
Phase
II
Enrollment Status
Open to Enrollment